Logo

Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop… read more

Healthcare

Biotechnology

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$28.95

Price

+0.52%

$0.15

Market Cap

$2.783b

Mid

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-33.3%

3y CAGR

-5.9%

5y CAGR
Earnings

-$315.687m

-28.2%

1y CAGR

-34.2%

3y CAGR

-25.6%

5y CAGR
EPS

-$2.98

-20.6%

1y CAGR

-11.6%

3y CAGR

+0.9%

5y CAGR
Book Value

$233.293m

$340.045m

Assets

$106.752m

Liabilities

$61.529m

Debt
Debt to Assets

18.1%

-0.2x

Debt to EBITDA
Free Cash Flow

-$258.123m

-28.4%

1y CAGR

-25.1%

3y CAGR

-19.2%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases